Cellectar Biosciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

STOCK-BASED COMPENSATION (Details)

STOCK-BASED COMPENSATION (Details) (USD $)	3 Months Ended
STOCK-BASED COMPENSATION (Details) (USD $)	Mar. 31, 2015	Mar. 31, 2014
Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Line Items]
Total stock-based compensation	$ 191,790us-gaap_ShareBasedCompensation	$ 262,526us-gaap_ShareBasedCompensation
Employee and Director Stock Option Grants [Member]
Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Line Items]
Total stock-based compensation	188,692	247,812
Employee and Director Stock Option Grants [Member] \| Research and Development [Member]
Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Line Items]
Total stock-based compensation	43,356	63,427
Employee and Director Stock Option Grants [Member] \| General and Administrative [Member]
Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Line Items]
Total stock-based compensation	145,336	184,385
Non Employee Consultant Stock Option Grants [Member]
Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Line Items]
Total stock-based compensation	3,098	14,714
Non Employee Consultant Stock Option Grants [Member] \| Research and Development [Member]
Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Line Items]
Total stock-based compensation	$ 3,098	$ 14,714